We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pluri Inc | NASDAQ:PLUR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.68 | 4.52 | 4.60 | 0 | 01:00:00 |
Conference: Bio-Europe SpringDate: March 18-20, 2024Location: BarcelonaPluri’s Chief Business Development Officer-Pharma Efrat Kaduri will attend the event. BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings.
Conference: Advanced Therapies 2024Date: March 19-20, 2024Location: LondonPluri’s Chief Technology Officer Lior Raviv will participate in a panel discussion titled: Points to consider when building supply chain operations from scratch on Tuesday, March 19, 2024 at 1:40 PM. He will also give a presentation titled: Unleashing the Allogeneic Potential by Using Large Scale Automated Manufacturing Platforms on Wednesday, March 20, 2024 at 2:40 PM.Pluri’s Chief Commercial Officer PluriCDMO Andy Lewin will attend the event. The Advanced Therapies congress is Europe’s largest cell and gene therapy conference and exhibition. The event brings together the world leaders in advanced therapy medicinal product development and the most senior executives in charge of the latest tech and strategies that are driving the industry forward.
Conference: CISH Impact Investments Holdings ConferenceDate: March 28, 2024Location: Online EventPluri’s Chief Executive Officer & President Yaky Yanay will be presenting at the conference on Thursday, March 28, 2024 at 2:20 PM.CISH Impact Investments Holdings Conference is a global event on impact opportunities and investments in promising technology companies that have a positive impact on the community and the environment.
Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com
About Pluri
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services. To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com/ Jessica Daitch at Jessica@quantum-corp.com
1 Year Pluri Chart |
1 Month Pluri Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions